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A PILOT STUDY EVALUATING THE SAFETY AND EFFICACY OF AMD3100
FOR THE MOBILIZATION AND TRANSPLANTATION OF HLA-MATCHED
SIBLING DONOR HEMATOPOIETIC STEM CELLS IN PATIENTS WITH
ADVANCED HEMATOLOGICAL MALIGNANCIES
Devine, S.M.1, Todt, L.2, Bonde, J.2, Hess, D.2, Devine, H.1, Nolta, J.2,
Link, D.2, Calandra, G.3, Bridger, G.3, DiPersio, J.F.2 1. Ohio State
University, Columbus, OH; 2. Washington University, St. Louis, MO;
3. Anormed Inc., Langley, BC, Canada.
We are studying an antagonist of the SDF-1/CXCR4 interac-
tion, AMD3100, as a single agent to procure mobilized blood from
allogeneic donors. Eleven HLA identical siblings received one or
two doses of AMD3100 at 240 g/kg subcutaneously followed in
four hours by leukapheresis (LP). After successful collection and a
one week washout period, the same donors were remobilized using
a standard G-CSF dose and schedule. AMD3100 administration
resulted in a median 7-fold increase in peripheral CD34 cell
count from baseline within 4-6 hours compared to 21-fold after
ﬁve days of G-CSF. Nine of eleven donors mobilized following
AMD3100 collected at least 1.9  106 CD34 cells/kg recipient
weight following 1 (n  5) or 2 (n  4) LP procedures. Allografts
mobilized following AMD3100 contained less CD34 cells but
proportionately greater numbers of T-,B-, and NK-cells compared
to G-CSF allografts. AMD3100 was well tolerated and no donors
experienced any greater than grade 1 toxicity. One donor could not
tolerate apheresis and was taken off study. Eight patients have been
transplanted using the AMD3100 mobilized allografts. Two pa-
tients did not receive allografts due to progressive disease. The
median age of the recipients was 45 years (range 32-53). Three had
AML, one ALL, one CLL, one accelerated CML, and two non-
Hodgkin’s lymphoma. With a median follow-up of 290 days (range
75 to 486 days), all eight evaluable pts have engrafted neutrophils
	500/l at a median of 10 days (range 8-13) and platelets
	20000/l at a median of 19 days (range 15-25). Acute GVHD
prophylaxis employed single agent cyclosporine only. One of eight
patients to date has experienced grade 2-4 acute GVHD, and that
pt expired due to refractory GVHD. Two of ﬁve evaluable patients
have experienced extensive chronic GVHD requiring immunosup-
pressive therapy. All pts achieved early full donor chimerism of
peripheral T- and myeloid cell compartments which has been
sustained. Seven of the eight pts currently survive progression free
with full trilineage hematopoiesis. In summary, grafts mobilized
following AMD3100 differ from G-CSF mobilized allografts in the
content of CD34 and immune effector cells yet appear to recon-
stitute hematopoiesis similarly. The risk of acute GVHD does not
seem to be increased despite the transplantation of higher T-cell
doses. It appears that a chemokine antagonist given alone can safely
and rapidly induce the mobilization of a functionally competent
hematopoietic allograft.
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PHASE 2 STUDY OF TARGETED INTRAVENOUS BUSULFAN (IV BU)
COMBINED WITH FRACTIONATED TOTAL BODY IRRADIATION (FTBI)
AND ETOPOSIDE (VP-16) AS PREPARATIVE REGIMEN FOR ALLOGE-
NEIC PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT) FOR
PATIENTS WITH POOR RISK LEUKEMIA
Stein, A.S.1, O’Donnell, M.R.1, Dagis, A.1, Krishnan, A.1,
Nademanee, A.1, Nakamura, R.1, Parker, P.M.1, Popplewell, L.1,
Pullarkat, V.1, Rodriguez, R.1, Rosenthal, J.1, Smith, E.P.1,
Snyder, D.S.1, Spielberger, R.2, Synold, T.1, Vora, N.1, Zain, J.1,
Sarkodee-Adoo, C.3, Forman, S.J.1 1. City of Hope Comprehensive
Cancer Center, Duarte, CA; 2. City of Hope Samaritan Transplant
Program Phoenix, Phoenix, AZ; 3. City of Hope Kaiser Permanente
Transplant Program, Duarte, CA.
Between 3/2000 and 11/2004 30 patients with high risk of relapse
post myeloablative SCT received an augmented conditioning reg-
imen consisting of IVBU followed by FTBI 1200 cGy in 10
fractions over 4 days and VP-16 30 mg/kg. BU was administered at
18 mg/m2 targeted for an AUC of 700-900 M  min every 6
hours  16 doses. Based on pharmacokinetics, doses for each
patient could be adjusted up to a maximum of 32 mg/m2 to
achieved targeted AUC. 24 patients had active leukemia (AML 9
induction failure (IF), 7 relapse, 1 untreated MDS evolved to AML,
ALL 4 IF and 3 relapse) while 6 patients had remission marrows at
time of SCT (3 AML with poor risk cytogenetics and 3 with prior
MDS evolved to AML). All patients received PBSC from HLA
matched sibling donors. GVHD prophylaxis was CSA and MMF.
With a median follow-up of 35 months (3.3, 55.3), the 2 year
probabilities of overall and event free survival were 63% (95% CI
38-82%) and 64% (95% CI 39-83%) for patients with active AML
and 50% (95% CI 17-83%) and 33% (95% CI 8-73%), respec-
tively, for ALL. The probability of relapse for AML and ALL with
active disease was 13% (95% CI 3-40%) and 58% (95% CI 19-
89%) respectively. The 2 year probability of both overall and event
free survival was 83% (95% CI 37-98%) for patients with AML in
remission at time of SCT with no relapses to date. The 100 day
non relapse mortality was 7% (95% CI 2-23%) and overall non
relapse mortality assessed at date of analysis was 30%. Grade 2-4
acute GVHD occurred in 60%; limited chronic GVHD was
present in 36% and extensive in 56% of eligible patients. This
regimen was very effective in reducing relapse in patients both with
high risk myeloid malignancy in remission and relapse at time of
SCT. It was less effective in reducing relapse in patients with ALL
transplanted with active disease.
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PENTOSTATIN IN REFRACTORY ACUTE AND CHRONIC GVHD. A SINGLE
CENTER EXPERIENCE
Arcos, M.J., Diez-Campelo, M., Caballero, M.D., Vidan, J.,
Perez-Simon, J.A., Vazquez, L., Canizo, M.C., Castilla, C.,
Mateos, J.J., Lopez, O., Perez, E., Encinas, C., Graciani, I.,
San Miguel, J.F. Hospital Clinico de Salamanca, Salamanca, Spain.
Graft-versus-host disease (GVHD) is a major complication of
allogeneic bone marrow transplantation. In refractory acute
(aGVHD) and chronic (cGVHD) GVHD, mortality is very high.
Pentostatin, a potent inhibitor of adenosine deaminase, induces
lymphocyte apoptosis and may be useful in the treatment of this
condition. Patients and Methods: We have conducted a prospec-
tive study of pentostatin in patients with refractory acute and
cGVHD. Ten patients were enrolled in the analysis, 7 with refrac-
tory aGVHD (2 skin, 5 gut and 2 liver aGVHD with a grade 2 and
3 in 2 and 5 patients, respectively) and 3 with refractory extensive
cGVHD (2 skin, 1 gut and 1 sinew as organs involved). Pentostatin
dose was 1.5-2.5 mg/m2/d by intravenous injection for 3 days
among seven patients diagnosed of refractory aGVHD (one patient
required an additional dose on day 14 and 28) and 2.5 mg/m2/
week during 4 weeks and them 4 mg/m2/2 weeks regarding 3
refractory chronic GVHD patients. Results: Regarding refractory
aGVHD, response rate was 79%, with 2 (28.5%) out of 7 patients
in complete response (CR) and 3 (43%) out of 7 patients in partial
response (PR). Two (28.5%) out of 7 aGVHD patients did not
respond. Regarding refractory cGVHD all patients included
reached responses to pentostatin, all of them PR. Only 2 out of 10
patients receiving pentostatin as refractory GVHD treatment died
due to GVHD complications. No more incidence of late infections
and other complications were observed in this subgroup of pa-
tients, the drug was well tolerated. Conclusion: Pentostatin has
activity in patients with refractory acute and chronic GVHD with-
out important side effects.
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RENAL DYSFUNCTION AFTER ALLOGENEIC STEM CELL TRANSPLANTA-
TION: RISK FACTORS AND OUTCOME
Oshima, K.1, Kanda, Y.1,2, Sato, H.2, Watanabe, T.2, Hosoya, N.1,
Chiba, S.1, Kurokawa, M.2 1. Department of Cell Therapy & Trans-
plantation Medicine, Tokyo, Japan; 2. Department of Hematology and
Oncology, Tokyo, Japan.
Background: Allogeneic hematopoietic stem cell transplantation
(allo-HSCT) can potentially cure various malignant and non-ma-
lignant hematological disorders. However, allo-HSCT is associ-
ated with a high risk of treatment-related mortality. Renal dys-
function is one of frequent, life-threatening treatment-related
toxicities. In this study, we evaluated the incidence and risk factors
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for renal dysfunction after allo-HSCT. Methods: The records of
178 adult patients who underwent allo-HSCT at the University of
Tokyo Hospital between September 1999 and July 2005 were
retrospectively analyzed. Renal dysfunction was classiﬁed accord-
ing to Bearman’s criteria: grade 0  normal renal function; grade
I apparent buttwofold increase in serum creatinine; grade II
twofold increase in serum creatinine; grade III  twofold
increase in serum creatinine and need for dialysis. Results: Of the
178 patients, 99 (55.6%) developed renal dysfunction at any grades
(grade I, 45 patients; grade II, 49 patients; grade III, 5 patients)
within 100 days after allo-HSCT (acute phase renal dysfunction;
ARD), 40% of whom did so within 28 days. For the development
of renal dysfunction before day 28, the use of vancomycin (P .09)
and high mean blood concentration of cyclosporine (P  .002)
were the risk factors with at least borderline signiﬁcance. On the
other hand, the development of bacteremia was signiﬁcantly asso-
ciated with the development of renal dysfunction between day 29
and 60 after transplantation (P  .018). Chronic phase renal
dysfunction (CRD) at 2 years after allo-HSCT was observed in
18.3% of the evaluable patients. The development of ARD was
signiﬁcantly associated with an increased incidence of CRD (P 
.001) and mortality (P  .003). Conclusions: The incidence of
ARD in this series was 55.6%, which was lower than that in the
previous reports. However, ARD was associated with a higher risk
of CRD and mortality. Patients with risk factors for ARD should
receive renoprotective procedures, including saline hydration and
the avoidance of other drugs with renal toxicity, if possible.
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ORAL BECLOMETHASONE DIPROPIONATE FOR THE TREATMENT OF
GASTROINTESTINAL ACUTE GRAFT VERSUS HOST DISEASE (GVHD)
Diez-Campelo, M., Perez-Simon, J.A., Castilla, C.,
Sanchez-Guijo, F.M., Caballero, M.D., Canizo, M.C., Vazquez, L.,
San Miguel, J.F. Hospital Clinico de Salamanca, Salamanca, Spain.
Treatment of gut GVHD relies on systemic immunosuppressive
therapy such as glucocorticoids. The risk of systemic immunosup-
pression includes infections, hypothalamic-pituitary-adrenal axis
suppression, myopathy, glucose intolerance, neuropsychiatric dis-
ease and bone demineralization, among others. Beclomethasone
dipropionate (BDP) is a topically active corticosteroid with a low
absorption, thus avoiding many of the deleterious side effects
associated with systemic immunosuppression. In the current study
we describe the safety and efﬁcacy of DBP as a single agent in a
series of 26 patients diagnosed with acute gut GVHD after allo-
geneic peripheral blood stem cell transplantation. All patients de-
veloped symptoms of acute GVHDwith biopsy proven gut GVHD
and received DBP as an oral solution in olive oil at a dose of 2 mg
q6h for 28 days. Symptoms of gut involvement consisted of nausea
(n  19), vomiting (n  12) and/or diarrhea (n  13). Seven
patients had grade 1 GI-GVHD (stage B overall aGVHD) and
nineteen had grade 2 GI-GVHD (stage C aGVHD). Median day
for DPB treatment was 48 after transplant. Overall response rate
was 81%, 19 patients achieve complete response (70%) and 3
partial response (11%). There were no differences regarding acute
gut GVHD symptoms and response rate. Only 7 did relapse among
responder patients. Overall percentage of patients ﬁnally requiring
steroid treatment after DPB was 41%. Cumulative incidence of
TRM is this series of stage B and C aGVHD patients was 30% and
overall survival 41% at 18 months. In the current study DBP was
well tolerated and showed efﬁcacy as a single agent in acute gut
GVHD treatment avoiding the requirement for systemic immu-
nosuppression in a signiﬁcant proportion of patients.
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ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR THE
TREATMENT OF HEMATOLOGIC MALIGNANCIES NOT IN REMISSION:
THE ANTI-TUMOR EFFECT OF REDUCED-INTENSITY CONDITIONING IS
COMPARABLE TO THAT OF CONVENTIONAL MYELOABLATIVE CONDI-
TIONING
Fukuda, T.1, Maruyama, D.1, Kato, R.1, Yamasaki, S.1, Usui, E.1,
Kim, S.-W.1, Mori, S.-I.1, Tanosaki, R.1, Tajima, K.1, Taniguchi, S.2,
Takaue, Y.1 1. National Cancer Center Hospital, Tokyo, Japan; 2.
Toranomon Hospital, Tokyo, Japan.
Myeloablative conditioning has been used to maximally reduce
the tumor burden before hematopoietic cell transplantation
(HCT) in patients not in remission. However, the potential of
reduced-intensity conditioning has not been fully questioned. To
address this point, we retrospectively reviewed the medical records
of 132 patients with hematologic malignancies not in remission
who underwent allogeneic HCT at our center between 2000 and
2004. Disease status was primary refractory (n  42), refractory
relapse (n  65), blastic crisis or accelerated phase of chronic
myelogenous leukemia (CML, n  8), or untreated disease (n 
17). Donors included HLA-matched (n  54) or mismatched (n 
16) relatives and unrelated volunteers (n  62). Stem cell source
was G-CSF-mobilized peripheral blood stem cell (n  70), bone
marrow (n  47), or cord blood (n  15). We compared the
non-relapse mortality (NRM), relapse or progressive disease (PD),
overall survival (OS), and progression-free survival (PFS) of pa-
tients who received ﬂudarabine-based reduced-intensity (RIST
group, n  80) or conventional myeloablative conditioning (CST
group, n  52). The median age of the RIST group was signiﬁ-
cantly older than that of the CST group (53 years vs 40 years, P 
.0001). The RIST group included higher proportions of patients
with lymphoid disease, those with more comorbidity, and those
who received grafts from HLA-matched relatives. Disease status
was similar between the two groups. The probabilities of achieving
complete remission in the RIST vs CST groups were 70% vs 83%,
respectively. The 2-year probabilities of NRM (38% vs 37%), PD
(49% vs 52%), OS (38% vs 29%), and PFS (29% vs 27%) in the
RIST vs CST groups were not signiﬁcantly different. Multivariate
analyses revealed that a higher HCT-speciﬁc comorbidity index
and transplant from donors other than HLA-matched relatives
were associated with increased risks of high NRM and poor OS,
and patients who did not receive aggressive chemotherapy within 2
months before HCT were associated with a lower risk of PD and
better PFS. After adjusting for these variables, the risks of NRM,
PD, OS, and PFS in the RIST group were not signiﬁcantly dif-
ferent from those in the CST group. In conclusion, our study
suggests that the anti-tumor effect of RIST is comparable to that
of conventional myeloablative HCT, and hence RIST is feasible
for the treatment of hematologic malignancies not in remission. A
prospective study is warranted to conﬁrm this conclusion.
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DURABLE ENGRAFTMENT OF PURIFIED ALLOGENEIC HEMATOPOIETIC
STEM CELLS FOLLOWING NON-MYELOABLATIVE CONDITIONING
Muchmore, M.-E.A., Burge, M.J., Shizuru, J.A. Stanford University
School of Medicine, Stanford, CA.
Transplantation of puriﬁed allogeneic hematopoietic stem cells
(HSC) has the potential to be a curative treatment for autoimmune
diseases. Before it becomes a viable therapy, however, the treat-
ment-related mortality and difﬁculty of achieving engraftment
must be addressed. Our research has focused on developing non-
myeloablative regimens that lead to donor-derived engraftment of
puriﬁed HSC in a murine model. Total lymphoid irradiation (TLI)
consists of low-dose fractionated irradiation targeted to the thy-
mus, abdomen, and peripheral nodes, while the skull, lungs, and
long bones remain shielded. The non-myeloablative conditioning
regimen of TLI and anti-thymocyte globulin (ATG) was followed
by HSC transplantation. HSC were isolated by the composite
phenotype of Thy1.1, c-kit, Sca-1, and lineage (KTLS).
We tested HSC transplantations across three major histocompat-
ibility complex (MHC)-matched strain combinations known
through previous studies in our group to have signiﬁcantly differ-
ent barriers to engraftment. In all three strain combinations we
observed stable mixed chimerism (approximately 50% donor-de-
rived cells by day 90) when high doses (10000/mouse) of HSC were
administered. In prior studies from our laboratory in a spontane-
ously arising autoimmune diabetes model, we demonstrated that
mixed allogeneic chimerism alone following non-myeloablative
conditioning was sufﬁcient to block autoimmune pathogenesis. To
study how TLI/ATG allows engraftment, we have examined the
marrow of TLI/ATG conditioned, untransplanted animals.
Though TUNEL and caspase-3 assays do not show a signiﬁcant
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